Breast Cancer Res Treat (2018) 168:69–77 https://doi.org/10.1007/s10549-017-4550-8 CLINICAL TRIAL 21‑Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B‑28/NRG Oncology 1,2 3 1,4 5 3 Eleftherios P. Mamounas · Gong Tang · Soonmyung Paik · Frederick L. Baehner · Qing Liu · 3 1 5 5 5 5 Jong‑Hyeon Jeong · S. Rim Kim · Steven M. Butler · Farid Jamshidian · Diana B. Cherbavaz · Amy P. Sing · 5 1,6 1 1,6 3 Steven Shak · Thomas B. Julian · Barry C. Lembersky · D. Lawrence Wickerham · Joseph P. Costantino · 1,6 Norman Wolmark Received: 16 October 2017 / Accepted: 24 October 2017 / Published online: 11 November 2017 © Springer Science+Business Media, LLC 2017 Abstract ER-positive, tamoxifen-treated patients with RS assessment. Background The 21-gene recurrence score (RS) predicts Median follow-up time was 11.2 years. outcome and benefit from adjuvant chemotherapy benefit in Results In univariate analyses, RS was a significant predic - breast cancer patients treated with adjuvant endocrine ther- tor of outcome. In multivariate analyses, RS remained a sig- apy. In the NSABP B-28 study, we evaluated the 21-gene nificant independent predictor of outcome beyond clinico- RS for its prognostic impact and its ability to predict ben- pathologic factors, age, and type of surgery (p < 0.001). In efit from paclitaxel (P) in node-positive, estrogen receptor- the study population
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 11, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera